Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
0.2110
-0.1289 (-37.92%)
At close: Jun 27, 2025, 4:00 PM
0.2081
-0.0029 (-1.37%)
After-hours: Jun 27, 2025, 7:59 PM EDT
HSDT Revenue
Helius Medical Technologies had revenue of $49.00K in the quarter ending March 31, 2025, a decrease of -63.70%. This brings the company's revenue in the last twelve months to $434.00K, down -35.03% year-over-year. In the year 2024, Helius Medical Technologies had annual revenue of $520.00K, down -19.25%.
Revenue (ttm)
$434.00K
Revenue Growth
-35.03%
P/S Ratio
0.24
Revenue / Employee
$20,667
Employees
21
Market Cap
665.72K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 520.00K | -124.00K | -19.25% |
Dec 31, 2023 | 644.00K | -143.00K | -18.17% |
Dec 31, 2022 | 787.00K | 265.00K | 50.77% |
Dec 31, 2021 | 522.00K | -139.00K | -21.03% |
Dec 31, 2020 | 661.00K | -835.00K | -55.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HSDT News
- 17 hours ago - Helius Medical Technologies Announces Reverse Stock Split - GlobeNewsWire
- 11 days ago - Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 15 days ago - Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire
- 16 days ago - Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 23 days ago - Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering - GlobeNewsWire
- 23 days ago - Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria - GlobeNewsWire
- 5 weeks ago - Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting - GlobeNewsWire
- 6 weeks ago - Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire